CytoMed AGM backs all 2026 shareholder resolutions

CytoMed Therapeutics Limited reported the results of its Annual General Meeting of Shareholders held on May 22, 2026 in Singapore.

Accepted by SEC EDGAR 06/03/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reported the results of its Annual General Meeting of Shareholders held on May 22, 2026 in Singapore. Holders of 7,162,501 ordinary shares, representing about 60.01% of issued and outstanding shares as of May 19, 2026, were represented, establishing a quorum.

All ten proposals were approved as recommended by the Board. Shareholders adopted the directors’ statement and audited financial statements for the year ended December 31, 2025, and re-elected Dr. Yew Chak Hua and Dr. Toh Keng Kiat as directors.

They approved a waiver related to the Singapore Code on Take-overs and Mergers, ratified WWC, P.C. and KE Trust PAC as independent auditors for 2026, approved directors’ fees of US$70,000 for 2026, and authorized the directors to issue ordinary shares until the next annual general meeting or the date it is required by law to be held, whichever is earlier.

Key Figures

Shares represented at AGM: 7,162,501 ordinary shares AGM quorum percentage: 60.01% Directors’ fees: US$70,000 +3 more

6 metrics

Shares represented at AGM 7,162,501 ordinary shares Present in person or by proxy at AGM; record date May 19, 2026

AGM quorum percentage 60.01% Portion of total issued and outstanding ordinary shares represented

Directors’ fees US$70,000 Approved fees for financial year ending December 31, 2026

Proposal One votes for 7,152,509 votes Adoption of directors’ statement and 2025 audited financial statements

Proposal Ten votes for 7,150,764 votes Authorization for directors to issue ordinary shares

AGM date and time May 22, 2026, 12:00 P.M. Singapore Time Annual General Meeting held in Singapore

Key Terms

ordinary resolution, Singapore Code on Take-overs and Mergers, independent registered public accounting firm, Directors’ fees, +1 more

5 terms

ordinary resolution regulatory

"By an ordinary resolution, to receive and adopt the Directors’ Statement, the audited financial statements..."

An ordinary resolution is a decision made by shareholders at a company meeting that is approved when more than half of the votes cast are in favor. Think of it like a household vote where a majority decides routine matters — it covers everyday corporate actions such as approving directors, routine policy changes, or distributions, and matters to investors because these majority-approved choices shape governance, management authority, and the company’s near-term direction.

Singapore Code on Take-overs and Mergers regulatory

"to approve waiver of the application of Singapore Code on Take-overs and Mergers issued by the Monetary Authority of Singapore."

A set of legally backed rules that governs how takeovers and mergers must be conducted in Singapore, covering disclosure, offer procedures, board conduct and shareholder rights. Think of it as traffic rules for corporate deals: it makes the process orderly, forces timely sharing of key information and protects minority investors from unfair treatment. Investors care because the code affects deal fairness, the timing and likelihood a bid succeeds, and the information they rely on when valuing shares.

independent registered public accounting firm financial

"to ratify the appointment of WWC, P.C., as the Company’s independent registered public accounting firm for the financial year ending December 31, 2026..."

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Directors’ fees financial

"to approve payment of Directors’ fees of US$70,000 for the financial year ending December 31, 2026."

issue ordinary shares financial

"to authorize the Directors to issue ordinary shares and make or grant offers, agreements or options..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What quorum was achieved at CytoMed Therapeutics (GDTC) 2026 AGM?

CytoMed achieved a 60.01% quorum at its 2026 AGM. Holders of 7,162,501 ordinary shares were present in person or by proxy, representing approximately 60.01% of the company’s issued and outstanding ordinary shares as of the May 19, 2026 record date.

Were all CytoMed Therapeutics (GDTC) 2026 AGM proposals approved?

Yes, all ten proposals at CytoMed’s 2026 AGM were approved. Shareholders backed the 2025 financial statements, director re-elections, waiver related to the Singapore Code on Take-overs and Mergers, auditor appointments, directors’ fees, adjournment authority, and share issuance authorization.

Which directors were re-elected at CytoMed Therapeutics (GDTC) 2026 AGM?

Shareholders re-elected Dr. Yew Chak Hua and Dr. Toh Keng Kiat. Both directors retired by rotation under Regulation 117 of the company’s Constitution and, being eligible, offered themselves for re-election and were approved by ordinary resolutions.

What directors’ fees did CytoMed Therapeutics (GDTC) shareholders approve for 2026?

Shareholders approved directors’ fees of US$70,000 for 2026. Proposal Eight, an ordinary resolution, authorized payment of directors’ fees of US$70,000 for the financial year ending December 31, 2026, receiving substantially more votes for than against.

Which auditors did CytoMed Therapeutics (GDTC) ratify for the 2026 financial year?

Shareholders ratified WWC, P.C. and KE Trust PAC as 2026 auditors. Two separate ordinary resolutions approved WWC, P.C. and KE Trust PAC as independent registered public accounting firms, with directors empowered to fix their remuneration at their discretion.

Did CytoMed Therapeutics (GDTC) authorize new share issuance at the 2026 AGM?

Yes, shareholders authorized directors to issue ordinary shares. Proposal Ten passed as an ordinary resolution, empowering directors to issue shares and grant related options until the next annual general meeting or the legally required date for holding that meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-41677

CytoMed Therapeutics Limited

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Annual General Meeting of Shareholders

On May 22, 2026, at 12:00 P.M., Singapore Time (May 22, 2026, at 12:00 A.M., Eastern Time), CytoMed Therapeutics Limited (the “Company”) held its Annual General Meeting of Shareholders (the “AGM”) at 1 Commonwealth Lane, #08-22, One Commonwealth, Singapore 149544. Holders of 7,162,501 ordinary shares of the Company were present in person or by proxy at the AGM, representing approximately 60.01% of the total issued and outstanding ordinary shares of the Company as of the record date of May 19, 2026, and therefore constituting a quorum of the shares outstanding and entitled to vote at the AGM as of the record date. All matters voted on at the AGM were approved as recommended by the Board of Directors of the Company. The final voting results for each matter submitted to a vote of shareholders at the AGM are as follows:

				For		Against		Abstain
Proposal One:		By an ordinary resolution, to receive and adopt the Directors’ Statement, the audited financial statements of the Company for the financial year ended December 31, 2025.		7,152,509		3,218		6,774
Proposal Two:		By an ordinary resolution, to receive and adopt the audited financial statements in relation to Form 20-F for the financial year ended December 31, 2025.		7,152,500		3,218		6,783
Proposal Three:		By an ordinary resolution, to approve the re-election of Dr. YEW Chak Hua, who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director.		7,148,109		6,492		7,900
Proposal Four:		By an ordinary resolution, to approve the re-election of Dr. TOH Keng Kiat who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director.		7,148,109		5,992		8,400
Proposal Five:		By an ordinary resolution, to approve waiver of the application of Singapore Code on Take-overs and Mergers issued by the Monetary Authority of Singapore.		7,148,799		8,092		5,610
Proposal Six:		By an ordinary resolution, to ratify the appointment of WWC, P.C., as the Company’s independent registered public accounting firm for the financial year ending December 31, 2026 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion.		7,154,600		6,118		1,783
Proposal Seven:		By an ordinary resolution, to ratify the appointment of KE Trust PAC as the Company’s independent registered public accounting firm for the financial year ending December 31, 2026 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion.		7,151,851		10,641		9
Proposal Eight:		By an ordinary resolution, to approve payment of Directors’ fees of US$70,000 for the financial year ending December 31, 2026.		7,145,750		14,742		2,009
Proposal Nine:		By an ordinary resolution, to adjourn the Annual General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal One, Proposal Two, Proposal Three, Proposal Four, Proposal Five, Proposal Six, Proposal Seven, Proposal Eight, and Proposal Ten.		7,155,659		6,842		0
Proposal Ten:		By an ordinary resolution, to authorize the Directors to issue ordinary shares and make or grant offers, agreements or options that might or would require the issuance of ordinary shares. If this resolution is approved, the authorization would be effective from the date of the AGM until (i) the conclusion of the next annual general meeting of the Company or (ii) the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.		7,150,764		8,463		3,274

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
Date: June 3, 2026	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
	Title:	Chairman and Director